GDTC

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: BLRX CYCN ERNA GNTA GTBP ICU INTS MBRX RKTO TOVX

Scroll to Statements

Index	-
Market Cap	12.19M
Enterprise Value	11.18M
Income	-3.04M
Sales	0.25M
Book/sh	0.43
Cash/sh	0.14
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	42
IPO	Apr 14, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	48.76
P/B	2.39
P/C	7.48
P/FCF	-
EV/EBITDA	-
EV/Sales	44.72
Quick Ratio	5.17
Current Ratio	5.17
Debt/Eq	0.07
LT Debt/Eq	0.06
Option/Short	No / Yes

EPS (ttm)	-0.26
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-8.01% -226.97%
Sales past 3/5Y	- -
EPS Y/Y TTM	-59.79%
Sales Y/Y TTM	373.88%
EPS Q/Q	-22.40%
Sales Q/Q	149.21%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	47.02%
Insider Trans	2.05%
Inst Own	0.14%
Inst Trans	-25.81%
ROA	-44.76%
ROE	-52.16%
ROIC	-56.14%
Gross Margin	-278.46%
Oper. Margin	-1434.50%
Profit Margin	-1224.43%
SMA20	-0.10%
SMA50	-1.27%
SMA200	-24.37%
Trades

Shs Outstand	11.83M
Shs Float	6.27M
Short Float	0.60%
Short Ratio	2.08
Short Interest	0.04M
52W High	3.68 -72.01%
52W Low	0.68 51.45%
Volatility	5.79% 8.30%
ATR (14)	0.09
RSI (14)	49.37
Beta	0.03
Rel Volume	3.00
Avg Volume	18.20K
Volume	54,655

Perf Week	5.64%
Perf Month	-9.36%
Perf Quarter	3.00%
Perf Half Y	-25.90%
Perf YTD	-22.85%
Perf Year	-53.18%
Perf 3Y	-70.49%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	5.00
Prev Close	0.98
Price	1.03
Change	5.10%

Jan-29-26 10:11AM	Cytomed Therapeutics refutes misleading claims, reaffirms clinical progress (TipRanks)
Jan-28-26 10:00AM	CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress (GlobeNewswire)
Jan-13-26 08:00AM	CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital (GlobeNewswire)
Dec-08-25 08:00AM	CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia (GlobeNewswire)
Nov-18-25 08:00AM	CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India (GlobeNewswire)
08:00AM	Loading…
Nov-06-25 08:00AM	CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy (GlobeNewswire)
Oct-22-25 08:00AM	CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% (GlobeNewswire)
Oct-15-25 08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
Oct-14-25 08:00AM	CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets (GlobeNewswire) +16.58%
Oct-02-25 07:00AM	CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic ?d T Cells in Acute Myeloid Leukemia (GlobeNewswire)
Aug-28-25 09:00AM	Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition (GlobeNewswire)
Aug-18-25 09:00PM	CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program (GlobeNewswire)
Jul-21-25 10:01AM	Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies (GlobeNewswire)
Apr-28-25 04:05PM	CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire) +5.70%
Feb-06-25 07:20AM	CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders (GlobeNewswire)
07:58AM	Loading…
Jan-07-25 07:58AM	CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India (TipRanks) -13.70%
06:45AM	CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India (Clinical Trials Arena)
Jan-06-25 07:00AM	CytoMed Therapeutics signs Business and Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India (GlobeNewswire)
07:00AM	CytoMed Therapeutics signs Business & Research Collaboration Agreement with Indias SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India (GlobeNewswire)
Nov-20-24 07:00AM	Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies (GlobeNewswire) +9.99%
Oct-07-24 07:00AM	CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant (GlobeNewswire) +10.04%
Oct-04-24 07:27AM	CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine (TipRanks) +7.94%
Oct-03-24 07:00AM	CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank (GlobeNewswire)
Sep-30-24 07:00AM	CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates (GlobeNewswire)
Sep-25-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 2 on September 26 (GlobeNewswire)
Sep-24-24 07:00AM	Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now (GlobeNewswire)
Aug-21-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now (GlobeNewswire)
Aug-20-24 07:00AM	Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now (GlobeNewswire) -8.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire) +14.29%
07:00AM	CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (?d) T Cells Technology for Solid and Liquid Cancers (GlobeNewswire)
07:00AM	Loading…
07:00AM	CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta ( ) T Cells Technology for Solid and Liquid Cancers (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Mar-20-24 08:30AM	CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration (ACCESSWIRE) -5.60%
Mar-18-24 06:00AM	CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies (GlobeNewswire) +5.63%
Mar-04-24 05:00AM	CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair (GlobeNewswire)
Jan-29-24 07:00AM	Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (GlobeNewswire)
Dec-05-23 07:30AM	CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology (PR Newswire)
Nov-17-23 09:21AM	CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update (PR Newswire) -8.60%
Nov-14-23 07:47AM	CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference (PR Newswire)
Oct-24-23 01:00PM	CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology (ACCESSWIRE) +5.04%
Sep-25-23 07:00AM	Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology (PR Newswire) +6.45%
Aug-29-23 09:00AM	CytoMed Expands Research Collaboration into China After Entering Into MOU (ACCESSWIRE)
Aug-17-23 07:30AM	CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit (Newsfile)
Aug-15-23 01:00PM	CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR T In Vivo Persistency (PR Newswire)
Aug-01-23 07:00AM	Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology (PR Newswire)
Jul-27-23 09:00AM	CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology (ACCESSWIRE)
Jul-14-23 10:52AM	Insiders Rewarded With S$77k Addition To Investment As CytoMed Therapeutics Stock Hits US$51m (Simply Wall St.)
Jul-06-23 07:00AM	A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US (PR Newswire) +6.23%
Jun-28-23 09:00AM	CytoMed Therapeutics Collaborates With Cancer Treatment Center to Advance Its Unique CAR-T Technology (NewMediaWire) +7.02%
May-11-23 09:00AM	CytoMed Therapeutics to Ring Nasdaq Closing Bell (PR Newswire) -6.31%
May-09-23 10:07AM	CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology (PR Newswire) -19.50%
Apr-13-23 08:00PM	CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering (PR Newswire)

CytoMed Therapeutics Ltd. is a biopharmaceutical company, which engages in the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy, and undertaking the research and development of immune cell and stem cell-based therapy. It operates through the Malaysia and Singapore geographical segments. The company was founded by Chee Kong Choo on March 9, 2018 and is headquartered in Singapore.

Executive ChairmanMr. Chee Kong Choo

Ph.D.Dr. Jieming Zeng M.D.

Chief Financial OfficerMs. Yvonne Goh

Chief Clinical OfficerDr. Tien Wee Luk M.D.

Chief Corporate OfficerMs. Yoong Ying Tan

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Choo Chee Kong	Director	May 13 '26	Buy	1.15	112,000	128,778	430,324	Jun 15 06:15 AM
mDR LTD	10% Owner	May 13 '26	Proposed Sale	0.84	117,337	98,094		May 13 10:03 AM
mDR LTD	10% Owner	Feb 12 '26	Proposed Sale	1.04	117,337	122,030		Feb 12 09:03 AM
mDR Ltd	10% Owner	Sep 23 '25	Proposed Sale	1.88	54,644	102,731		Sep 22 01:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CytoMed Therapeutics Ltd

Upgrade your Finviz experience